Cat. No.: HY-13318

Oseltamivir acid

(Synonyms: GS 4071; Ro 64-0802; Oseltamivir carboxylate)

76 Cited Publications

Avis client

Based on 76 publication(s) in Google Scholar

Oseltamivir acid (GS 4071), the active metabolite of Oseltamivir phosphate, is an orally bioavailable, potent and selective inhibitor of influenza virus neuraminidase (IC₅₀=2 nM) with activity against both influenza A and B viruses. Oseltamivir acid has an extremely weak ability to penetrate the BBB under normal physiological conditions, but its blood-brain barrier penetration is significantly enhanced under inflammatory conditions.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.50%
CAS No.: 187227-45-8
Formule: C₁₄H₂₄N₂O₄
Masse moléculaire:284.35

Stockage:

4°C, stored under nitrogen

* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

Oseltamivir acid Chemical Structure

CAS No.: 187227-45-8

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (76)
Solvant et solubilité
- In Vitro
- In Vivo
Protocole
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

IC₅₀ & Target

IC50: 2 nM (influenza virus neuraminidase)

Cellular Effect

Cell Line	Type	Value	Description	References
A549	CC₅₀	61.2 μM Compound: OSC	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 38608962]
Fibroblast	CC₅₀	>1000 μM Compound: OSC	Cytotoxicity against chicken embryo fibroblasts assessed as reduction in cell viability after 2 days by CCK-8 assay Cytotoxicity against chicken embryo fibroblasts assessed as reduction in cell viability after 2 days by CCK-8 assay	[PMID: 29407952]
Fibroblast	CC₅₀	>200 μM Compound: 1; OSC	Cytotoxicity against chicken embryo fibroblasts after 48 hrs by CCK-8 assay Cytotoxicity against chicken embryo fibroblasts after 48 hrs by CCK-8 assay	[PMID: 29965752]
Fibroblast	CC₅₀	>200 μM Compound: OSC	Cytotoxicity against chicken embryo fibroblasts assessed as reduction in cell viability after 48 hrs by CCK-8 assay Cytotoxicity against chicken embryo fibroblasts assessed as reduction in cell viability after 48 hrs by CCK-8 assay	[PMID: 30365885]
Fibroblast	CC₅₀	>200 μM Compound: OSC	Cytotoxicity against chicken embryo fibroblast assessed as reduction in cell viability after 48 hrs by CCK8 assay Cytotoxicity against chicken embryo fibroblast assessed as reduction in cell viability after 48 hrs by CCK8 assay	[PMID: 32092589]
Fibroblast	CC₅₀	>250 μM Compound: OSC	Cytotoxicity against chick embryo fibroblast cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay Cytotoxicity against chick embryo fibroblast cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay	[PMID: 35939763]
Fibroblast	CC₅₀	>200 μM Compound: OSC	Cytotoxicity against chicken embryo fibroblast cells assessed as reduction in cell growth incubated for 48 hrs by CCK-8 assay Cytotoxicity against chicken embryo fibroblast cells assessed as reduction in cell growth incubated for 48 hrs by CCK-8 assay	[PMID: 36931117]
Fibroblast	EC₅₀	12.32 μM Compound: OSC	Anti-influenza virus activity against Influenza A virus A/Goose/Guangdong/SH7/2013 (H5N1) infected in chicken embryo fibroblast assessed as protection against virus-induced cytopathic effect incubated for 48 hrs by CCK-8 assay Anti-influenza virus activity against Influenza A virus A/Goose/Guangdong/SH7/2013 (H5N1) infected in chicken embryo fibroblast assessed as protection against virus-induced cytopathic effect incubated for 48 hrs by CCK-8 assay	[PMID: 36931117]
Fibroblast	EC₅₀	2.96 μM Compound: OSC	Anti-influenza virus activity against Influenza A virus A/Goose/Jiangsu/1306/2014 (H5N8) infected in chicken embryo fibroblast assessed as protection against virus-induced cytopathic effect incubated for 48 hrs by CCK-8 assay Anti-influenza virus activity against Influenza A virus A/Goose/Jiangsu/1306/2014 (H5N8) infected in chicken embryo fibroblast assessed as protection against virus-induced cytopathic effect incubated for 48 hrs by CCK-8 assay	[PMID: 36931117]
Fibroblast	CC₅₀	>100 μM Compound: OSC	Cytotoxicity against chicken embryo fibroblast cells assessed as reduction in cell growth by CCK-8 Cytotoxicity against chicken embryo fibroblast cells assessed as reduction in cell growth by CCK-8	[PMID: 37804770]
HEK293	IC₅₀	0.4 nM Compound: 3a	Inhibition of oseltamivir-resistant Influenza A virus A/WSN/1933(H1N1) recombinant wild type neuraminidase transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate ad Inhibition of oseltamivir-resistant Influenza A virus A/WSN/1933(H1N1) recombinant wild type neuraminidase transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate ad	[PMID: 27167096]
HEK293	IC₅₀	0.6 nM Compound: 3a	Inhibition of Influenza A virus A/Brisbane/10/2007(H3N2) recombinant wild type neuraminidase transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measure Inhibition of Influenza A virus A/Brisbane/10/2007(H3N2) recombinant wild type neuraminidase transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measure	[PMID: 27167096]
HEK293	IC₅₀	0.9 nM Compound: 3a	Inhibition of oseltamivir-resistant Influenza A virus A/Vietnam/1194/2004(H5N1) recombinant wild type neuraminidase transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by sub Inhibition of oseltamivir-resistant Influenza A virus A/Vietnam/1194/2004(H5N1) recombinant wild type neuraminidase transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by sub	[PMID: 27167096]
HEK293	IC₅₀	1 nM Compound: 3a	Inhibition of Influenza A virus A/Shanghai/01/2014(H7N9) recombinant wild type neuraminidase transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measure Inhibition of Influenza A virus A/Shanghai/01/2014(H7N9) recombinant wild type neuraminidase transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measure	[PMID: 27167096]
HEK293	IC₅₀	26 nM Compound: 3a	Inhibition of oseltamivir-resistant Influenza A virus A/Vietnam/1194/2004(H5N1) recombinant neuraminidase H275Y mutant transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by Inhibition of oseltamivir-resistant Influenza A virus A/Vietnam/1194/2004(H5N1) recombinant neuraminidase H275Y mutant transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by	[PMID: 27167096]
HEK293	IC₅₀	4371 nM Compound: 3a	Inhibition of Influenza A virus A/Brisbane/10/2007(H3N2) recombinant neuraminidase R292K mutant transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition meas Inhibition of Influenza A virus A/Brisbane/10/2007(H3N2) recombinant neuraminidase R292K mutant transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition meas	[PMID: 27167096]
HEK293	IC₅₀	49 nM Compound: 3a	Inhibition of Influenza A virus A/WSN/1933(H1N1) recombinant neuraminidase H275Y mutant transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measured aft Inhibition of Influenza A virus A/WSN/1933(H1N1) recombinant neuraminidase H275Y mutant transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measured aft	[PMID: 27167096]
HEK293	IC₅₀	>83000 nM Compound: 3a	Inhibition of Influenza A virus A/Brisbane/10/2007(H3N2) recombinant neuraminidase E119A mutant transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition meas Inhibition of Influenza A virus A/Brisbane/10/2007(H3N2) recombinant neuraminidase E119A mutant transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition meas	[PMID: 27167096]
HEK-293T	CC₅₀	>250 μM Compound: OSV	Cytotoxicity against HEK293T cells assessed as decrease in cell viability after 24 hrs by MTT assay Cytotoxicity against HEK293T cells assessed as decrease in cell viability after 24 hrs by MTT assay	[PMID: 30142611]
HeLa	CC₅₀	>1000 μM Compound: B	Cytotoxicity against human HeLa cells measured at 24 hrs post dose Cytotoxicity against human HeLa cells measured at 24 hrs post dose	[PMID: 28182988]
HeLa	CC₅₀	>1000 μM Compound: B	Cytotoxicity against human HeLa cells measured at 48 hrs post dose Cytotoxicity against human HeLa cells measured at 48 hrs post dose	[PMID: 28182988]
MDCK	CC₅₀	17.12 μM Compound: Oseltamivir carboxylic acid	Cytotoxicity against MDCK cells by MTT assay Cytotoxicity against MDCK cells by MTT assay	[PMID: 18640042]
MDCK	EC₅₀	>100 μM Compound: 5	Antiviral activity against Oseltamivir-resistant Influenza A virus A/Berlin/55/08(H1N1) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs Antiviral activity against Oseltamivir-resistant Influenza A virus A/Berlin/55/08(H1N1) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs	[PMID: 24422530]
MDCK	EC₅₀	5.21 μM Compound: 5	Antiviral activity against Influenza A virus A/Jena/5258/2009(H1N1) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs Antiviral activity against Influenza A virus A/Jena/5258/2009(H1N1) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs	[PMID: 24422530]
MDCK	EC₅₀	11026 nM Compound: 1a, OC	Antiviral activity against Influenza A virus A/WSN/1933(H1N1) harboring neuraminidase H275Y mutant infected in MDCK cells assessed as virus-mediated cytopathic effect after 48 hrs by CellTiter96 assay Antiviral activity against Influenza A virus A/WSN/1933(H1N1) harboring neuraminidase H275Y mutant infected in MDCK cells assessed as virus-mediated cytopathic effect after 48 hrs by CellTiter96 assay	[PMID: 25456388]
MDCK	EC₅₀	28.2 nM Compound: 1a, OC	Antiviral activity against Influenza A virus A/WSN/1933(H1N1) infected in MDCK cells assessed as virus-mediated cytopathic effect after 48 hrs by CellTiter96 assay Antiviral activity against Influenza A virus A/WSN/1933(H1N1) infected in MDCK cells assessed as virus-mediated cytopathic effect after 48 hrs by CellTiter96 assay	[PMID: 25456388]
MDCK	CC₅₀	>100 μM Compound: Oseltamivir carboxylate	Cytotoxicity against MDCK cells assessed as cell viability measured after 4 days by formazan-based MTS assay Cytotoxicity against MDCK cells assessed as cell viability measured after 4 days by formazan-based MTS assay	[PMID: 27112451]
MDCK	EC₅₀	1.4 μM Compound: Oseltamivir carboxylate	Antiviral activity against Influenza A virus A/PR/8/34 infected in MDCK cells assessed as reduction of virus-induced cytopathic effect measured after 4 days by formazan-based MTS assay Antiviral activity against Influenza A virus A/PR/8/34 infected in MDCK cells assessed as reduction of virus-induced cytopathic effect measured after 4 days by formazan-based MTS assay	[PMID: 27112451]
MDCK	EC₅₀	4 μM Compound: Oseltamivir carboxylate	Antiviral activity against Influenza A virus A/PR/8/34 infected in MDCK cells assessed as reduction of virus induced cytopathic effect measured by visual scoring of cytopathic effect Antiviral activity against Influenza A virus A/PR/8/34 infected in MDCK cells assessed as reduction of virus induced cytopathic effect measured by visual scoring of cytopathic effect	[PMID: 27112451]
MDCK	EC₅₀	5.5 nM Compound: 3a	Antiviral activity against oseltamivir-resistant Influenza A virus A/WSN/1933(H1N1) infected in MDCK cells assessed as protection against virus-induced cytopathic effect after 48 hrs by CellTiter 96 AQueous Non-Radioactive cell proliferation assay Antiviral activity against oseltamivir-resistant Influenza A virus A/WSN/1933(H1N1) infected in MDCK cells assessed as protection against virus-induced cytopathic effect after 48 hrs by CellTiter 96 AQueous Non-Radioactive cell proliferation assay	[PMID: 27167096]
MDCK	CC₅₀	>1 x 10⁵ nM Compound: 3a	Cytotoxicity against MDCK cells after 48 hrs by CellTiter 96 AQueous Non-Radioactive cell proliferation assay Cytotoxicity against MDCK cells after 48 hrs by CellTiter 96 AQueous Non-Radioactive cell proliferation assay	[PMID: 27167096]
MDCK	CC₅₀	>1000 μM Compound: B	Cytotoxicity against MDCK cells measured at 48 hrs post dose Cytotoxicity against MDCK cells measured at 48 hrs post dose	[PMID: 28182988]
MDCK	CC₅₀	>1000 μM Compound: B	Cytotoxicity against MDCK cells measured at 24 hrs post dose Cytotoxicity against MDCK cells measured at 24 hrs post dose	[PMID: 28182988]
MDCK	CC₅₀	>100 μM Compound: 2b; OC	Cytotoxicity against MDCK cells after 48 hrs by CellTiter96 aqueous non-radioactive cell proliferation assay Cytotoxicity against MDCK cells after 48 hrs by CellTiter96 aqueous non-radioactive cell proliferation assay	[PMID: 29843102]
MDCK	CC₅₀	>250 μM Compound: 1; OSC	Cytotoxicity against MDCK cells after 48 hrs by MTT assay Cytotoxicity against MDCK cells after 48 hrs by MTT assay	[PMID: 29965752]
MDCK	CC₅₀	>250 μM Compound: OSV	Cytotoxicity against MDCK cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against MDCK cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 30142611]
MDCK	CC₅₀	>250 μM Compound: OSC	Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30365885]
MDCK	CC₅₀	>20 μM Compound: Oseltamivir carboxylate	Cytotoxicity against MDCK cells after 48 hrs by neutral red uptake assay Cytotoxicity against MDCK cells after 48 hrs by neutral red uptake assay	[PMID: 30429954]
MDCK	CC₅₀	>30 μg/mL Compound: Oseltamivir carboxylate	Cytotoxicity in MDCK cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity in MDCK cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31375291]
MDCK	CC₅₀	>1000 μM Compound: 5; OC	Cytotoxicity against dog MDCK cells assessed as reduction in cell viability incubated for 72 hrs by celltiterglo reagent based assay Cytotoxicity against dog MDCK cells assessed as reduction in cell viability incubated for 72 hrs by celltiterglo reagent based assay	[PMID: 31708183]
MDCK	CC₅₀	713.4 μM Compound: OMVA	Cytotoxicity against dog MDCK cells assessed as reduction in cell viability by MTT assay Cytotoxicity against dog MDCK cells assessed as reduction in cell viability by MTT assay	[PMID: 31744778]
MDCK	EC₅₀	7.1 nM Compound: OMVA	Antiviral activity against Influenza A virus (H1N1) infected in dog MDCK cells assessed as reduction in log2HA titer incubated for 3 to 4 days by CPE assay Antiviral activity against Influenza A virus (H1N1) infected in dog MDCK cells assessed as reduction in log2HA titer incubated for 3 to 4 days by CPE assay	[PMID: 31744778]
MDCK	CC₅₀	66 μM Compound: Oseltamivir carboxylate	Cytotoxicity against MDCK cells Cytotoxicity against MDCK cells	[PMID: 32360104]
MDCK	IC₅₀	13 μM Compound: Oseltamivir carboxylate	Inhibition of M2 proton channel in Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as inhibition of viral infection Inhibition of M2 proton channel in Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as inhibition of viral infection	[PMID: 32360104]
MDCK	CC₅₀	>250 μM Compound: OSC	Cytotoxicity against MDCK cells assessed as reduction in cell viability by MTT assay Cytotoxicity against MDCK cells assessed as reduction in cell viability by MTT assay	[PMID: 33385836]
MDCK	CC₅₀	>100 μM Compound: Oseltamivir carboxylate	Cytotoxicity in dog MDCK cells assessed as reduction in cell viability measured after 3 days by beckman coulter counting method Cytotoxicity in dog MDCK cells assessed as reduction in cell viability measured after 3 days by beckman coulter counting method	[PMID: 33894564]
MDCK	CC₅₀	250 μM Compound: OSC	Cytotoxicity against dog MDCK cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay Cytotoxicity against dog MDCK cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay	[PMID: 34735766]
MDCK	CC₅₀	>100 μM Compound: Oseltamivir carboxylate	Cytotoxicity against MDCK cells infected with Influenza A virus A/Anhui/1/2013 (H7N9) assessed as reduction in cell viability Cytotoxicity against MDCK cells infected with Influenza A virus A/Anhui/1/2013 (H7N9) assessed as reduction in cell viability	[PMID: 34808389]
MDCK	CC₅₀	>100 μM Compound: Oseltamivir carboxylate	Cytotoxicity against MDCK cells infected with Influenza A virus A/Puerto Rico/8/34 (H1N1) assessed as reduction in cell viability Cytotoxicity against MDCK cells infected with Influenza A virus A/Puerto Rico/8/34 (H1N1) assessed as reduction in cell viability	[PMID: 34808389]
MDCK	CC₅₀	>100 μM Compound: OC	Cytotoxicity against MDCK cells assessed as reduction in cell viability measured after 72 hrs by CCK8 analysis Cytotoxicity against MDCK cells assessed as reduction in cell viability measured after 72 hrs by CCK8 analysis	[PMID: 34839161]
MDCK	CC₅₀	>250 μM Compound: OSC	Cytotoxicity against MDCK cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against MDCK cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 35939763]
MDCK	CC₅₀	>250 μM Compound: OSC	Cytotoxicity against dog MDCK cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay Cytotoxicity against dog MDCK cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay	[PMID: 36931117]
Vero	CC₅₀	>1000 μM Compound: B	Cytotoxicity against African green monkey Vero cells measured at 24 hrs post dose Cytotoxicity against African green monkey Vero cells measured at 24 hrs post dose	[PMID: 28182988]
Vero	CC₅₀	>1000 μM Compound: B	Cytotoxicity against African green monkey Vero cells measured at 48 hrs post dose Cytotoxicity against African green monkey Vero cells measured at 48 hrs post dose	[PMID: 28182988]

In Vitro

Oseltamivir acid inhibits virus replication in vitro and in vivo. Influenza B and A/H1N1 viruses appeare to be sensitive to Oseltamivir (mean B IC₅₀ value: 13 nM; mean H1N1 IC₅₀ value: 1.34 nM), while A/H1N2 and A/H3N2 viruses are more sensitive to Oseltamivir (mean H3N2 IC₅₀ value: 0.67 nM; mean H1N2 IC₅₀ value: 0.9 nM)^[3].
In neuraminidases inhibition assays with influenza A viruses, the IC₅₀ of RWJ-270201 (approximately 0.34 nM) is comparable to that of Oseltamivir carboxylate (0.45 nM) For influenza B virus isolates, the IC₅₀ of RWJ-270201 (1.36 nM) is comparable to that of Zanamivir (2.7 nM) and less than that of Oseltamivir carboxylate (8.5 nM)^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Oseltamivir acid (0.1, 1, or 10 mg/kg/day, twice daily by oral gavage) produces a dose-dependent antiviral effect against Vietnam/1203/04 (VN1203/04) virus. The 5-day regimen at 10 mg/kg/day protects 50% of mice; deaths in this treatment group are delayed and indicated the replication of residual virus after the completion of treatment. Dosages of 1 and 10 mg/kg/day significantly reduced virus titers in organs and provided 60% and 80% survival rates, respectively^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 187227-45-8
Appearance Solid
Masse moléculaire 284.35
Formule C₁₄H₂₄N₂O₄
Color White to off-white
SMILES

O=C(O)C1=C[C@H]([C@@H]([C@H](C1)N)NC(C)=O)OC(CC)CC
Synonyms

GS 4071; Ro 64-0802; Oseltamivir carboxylate
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

4°C, stored under nitrogen

* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

Publications (76)

All Cell Proliferation/Viability AssayIFWB

Sort by:

Journal Impact Factor

Nature

A pan-influenza antibody inhibiting neuraminidase via receptor mimicry. [Abstract]

2023 Jun;618(7965):590-597. PMID: 37258672
Nat Commun

Baloxavir outperforms oseltamivir, favipiravir, and amantadine in treating lethal influenza A(H5N1) HA clade 2.3.4.4b infection in mice. [Abstract]

2026 Feb 19. PMID: 41714318
Nat Commun

Genotype B3.13 influenza A(H5N1) viruses isolated from dairy cattle demonstrate high virulence in laboratory models, but retain avian virus-like properties. [Abstract]

2025 Jul 23;16(1):6771. PMID: 40695800
ACS Nano

Noninvasive visualization of respiratory viral infection using bioorthogonal conjugated near-infrared-emitting quantum dots. [Abstract]

2014 Jun 24;8(6):5468-77. PMID: 24797178
Sci Transl Med

Baloxavir alleviates severe disease and viremia in ferrets infected with avian- or bovine-origin influenza A(H5N1) virus. [Abstract]

2026 Feb 18;18(837):eadt3889. PMID: 41706870
Small

A Multiligand Architectural Photosensitizer That Targets Hemagglutinin on Envelope of Influenza Virus for Photodynamic Inactivation. [Abstract]

2020 May;16(20):e2000556. PMID: 32329578
J Environ Manage

Adsorption removal of antiviral drug oseltamivir and its metabolite oseltamivir carboxylate by carbon nanotubes: Effects of carbon nanotube properties and media. [Abstract]

2015 Oct 1:162:326-33. PMID: 26265601
Arch Pharm Res

The inhibitory effect of sodium baicalin on oseltamivir-resistant influenza A virus via reduction of neuraminidase activity. [Abstract]

2018 Jun;41(6):664-676. PMID: 29572682
Sci Data

High-throughput drug screening identifies novel therapeutics for Low Grade Serous Ovarian Carcinoma. [Abstract]

2024 Sep 19;11(1):1024. PMID: 39300112
Emerg Microbes Infect

Efficient airborne transmission of influenza D virus in ferret models and serological evidence of human exposure in Northeast China. [Abstract]

2025 Dec;14(1):2564308. PMID: 41069204
J Ethnopharmacol

Integrating bioinformatic analysis, network pharmacology, molecular docking and experimental validation to explore the mechanism of Tian Long Cha against influenza virus. [Abstract]

2025 Jun 12:349:119964. PMID: 40368255
J Ethnopharmacol

Synergistic effects of Lianhuaqingwen in combination with Oseltamivir and Baloxavir against seasonal influenza virus: In vitro and in vivo assessment. [Abstract]

2025 Feb 10;338(Pt 2):119091. PMID: 39528119
Talanta

Competitive ultrafiltration: A ligand-displacement strategy for rapid discovery of high-quality neuraminidase inhibitors from natural product mixtures. [Abstract]

2025 Oct 2;298(Pt B):128948. PMID: 41076770
Eur J Med Chem

Development of chalcone-like derivatives and their biological and mechanistic investigations as novel influenza nuclear export inhibitors. [Abstract]

2023 Dec 5:261:115845. PMID: 37804770
Eur J Med Chem

Discovery of hydrazide-containing oseltamivir analogues as potent inhibitors of influenza A neuraminidase. [Abstract]

2021 Oct 5:221:113567. PMID: 34082224
Eur J Med Chem

Discovery of a non-zwitterionic oseltamivir analogue as a potent influenza a neuraminidase inhibitor. [Abstract]

2020 Aug 15:200:112423. PMID: 32512482
Eur J Med Chem

Synthesis and biological evaluation of NH2-acyl oseltamivir analogues as potent neuraminidase inhibitors. [Abstract]

2017 Dec 1:141:648-656. PMID: 29107426
Anal Chim Acta

Machine learning-assisted affinity ultrafiltration for bioactive natural products discovery:Application to screening of neuraminidase inhibitors from medicinal herbs. [Abstract]

2025 Nov 8:1374:344522. PMID: 40983409
Int J Mol Sci

Antiviral Activity of Benzoic Acid Derivative NC-5 Against Influenza A Virus and Its Neuraminidase Inhibition. [Abstract]

2019 Dec 12;20(24):6261. PMID: 31842256
BMC Microbiol

Taurultam shows antiviral activity against SARS-CoV-2 and influenza virus. [Abstract]

2025 May 15;25(1):292. PMID: 40375181
Eur J Pharm Sci

Strain and sex differences in drug hydrolase activities in rodent livers. [Abstract]

2020 Jan 15:142:105143. PMID: 31726091
Molecules

Synthesis and Biological Evaluation of NH2-Sulfonyl Oseltamivir Analogues as Influenza Neuraminidase Inhibitors. [Abstract]

2019 Jun 10;24(11):2176. PMID: 31185617
Eur J Pharm Sci

Difference in substrate specificity of carboxylesterase and arylacetamide deacetylase between dogs and humans. [Abstract]

2018 Jan 1:111:167-176. PMID: 28966098
Molecules

Neuraminidase Inhibitory Activity and Constituent Characterization of Fagopyrum dibotrys. [Abstract]

2017 Nov 18;22(11):1998. PMID: 29156573
Molecules

Anti-Influenza Virus Activity and Constituents. Characterization of Paeonia delavayi Extracts. [Abstract]

2016 Aug 26;21(9):1133. PMID: 27571059
Eur J Pharm Sci

Comparison of substrate specificity among human arylacetamide deacetylase and carboxylesterases. [Abstract]

2015 Oct 12:78:47-53. PMID: 26164127
Sci Rep

Potential antiviral activity of rhamnocitrin against influenza virus H3N2 by inhibiting cGAS/STING pathway in vitro. [Abstract]

2024 Nov 16;14(1):28287. PMID: 39550441
Virol Sin

Inhibitory Activity of Honeysuckle Extracts against Influenza A Virus In Vitro and In Vivo. [Abstract]

2021 Jun;36(3):490-500. PMID: 33044658
RSC Med Chem

Discovery and characterization of a novel peptide inhibitor against influenza neuraminidase. [Abstract]

2020 Jan 22;11(1):148-154. PMID: 33479615
Antiviral Res

High-throughput screening for identification of influenza a inhibitors using a cell-based immunofluorescence assay. [Abstract]

2025 Aug:240:106209. PMID: 40484321
Antiviral Res

Influenza A(H1N1)pdm09 virus resistance to baloxavir, oseltamivir and sialic acid mimetics in single and dual therapies: Insights from human airway epithelia and murine models. [Abstract]

2025 Jul:239:106174. PMID: 40324597
Antiviral Res

Genotypic and phenotypic susceptibility of emerging avian influenza A viruses to neuraminidase and cap-dependent endonuclease inhibitors. [Abstract]

2024 Sep:229:105959. PMID: 38986873
Antiviral Res

Nafamostat mesylate as a broad-spectrum candidate for the treatment of flavivirus infections by targeting envelope proteins. [Abstract]

2022 Jun;202:105325. PMID: 35460703
Antiviral Res

Functional neuraminidase inhibitor resistance motifs in avian influenza A(H5Nx) viruses. [Abstract]

2020 Oct:182:104886. PMID: 32750468
Antiviral Res

Prophylaxis of ferrets with nitazoxanide and oseltamivir combinations is more effective at reducing the impact of influenza a virus infection compared to oseltamivir monotherapy. [Abstract]

2020 Apr;176:104751. PMID: 32088248
Antiviral Res

Cryptoporic acid E from Cryptoporus volvatus inhibits influenza virus replication in vitro. [Abstract]

2017 Jul:143:106-112. PMID: 28232246
Antiviral Res

Toll-like receptor 9 ligand D-type oligodeoxynucleotide D35 as a broad inhibitor for influenza A virus replication that is associated with suppression of neuraminidase activity. [Abstract]

2016 May:129:81-92. PMID: 26923882

Oseltamivir acid purchased from MedChemExpress. Usage Cited in: Antiviral Res. 2016 May:129:81-92. [Abstract]

MDCK cells are infected with K435E or H274Y in the absence of compounds and maintained at 35 °C in agarose with or without 10 nM Oseltamivir or 20 μg/mL D35, respectively.
Antiviral Res

Antiviral activity of SA-2 against influenza A virus in vitro/vivo and its inhibition of RNA polymerase. [Abstract]

2016 Mar:127:68-78. PMID: 26802558
Antiviral Res

Dextran sulfate-resistant A/Puerto Rico/8/34 influenza virus is associated with the emergence of specific mutations in the neuraminidase glycoprotein. [Abstract]

2014 Nov:111:69-77. PMID: 25234090

Oseltamivir acid purchased from MedChemExpress. Usage Cited in: Antiviral Res. 2014 Nov:111:69-77. [Abstract]

Plaque formation of different recombinant viruses in the presence of oseltamivir. MDCK cells are infected with recombinant viruses in the absence of Oseltamivir or DS and maintained in agarose overlay medium with 50 nM Oseltamivir or 100 μg/mL DS (DS), or without compounds (None) at 35 °C.
Antimicrob Agents Chemother

Development of Novel Anti-influenza Thiazolides with Relatively Broad-Spectrum Antiviral Potentials. [Abstract]

2020 Jun 23;64(7):e00222-20. PMID: 32312780
Antimicrob Agents Chemother

Emergence of H7N9 Influenza A Virus Resistant to Neuraminidase Inhibitors in Nonhuman Primates. [Abstract]

2015 Aug;59(8):4962-73. PMID: 26055368
J Infect Dis

Antiviral Susceptibility of Highly Pathogenic Avian Influenza A(H5N1) Viruses Circulating Globally in 2022-2023. [Abstract]

2024 Jun 14;229(6):1830-1835. PMID: 37770028
Virol J

Bisbenzylisoquinoline alkaloids inhibit influenza virus replication by disrupting endosomal acidification. [Abstract]

2025 Jun 4;22(1):181. PMID: 40468427
Virol J

Cirsimaritin inhibits influenza A virus replication by downregulating the NF-κB signal transduction pathway. [Abstract]

2018 May 21;15(1):88. PMID: 29783993
Influenza Other Respir Viruses

Efficacy of Oseltamivir Against Seasonal Influenza H1N1 and the Efficacy of a Novel Combination Treatment In Vitro and In Vivo in Mouse Studies. [Abstract]

2025 Oct;19(10):e70176. PMID: 41116245
Viruses

The Synergistic Effect of Baloxavir and Neuraminidase Inhibitors against Influenza Viruses In Vitro. [Abstract]

2024 Sep 14;16(9):1467. PMID: 39339943
Viruses

Bioprinted Multi-Cell Type Lung Model for the Study of Viral Inhibitors. [Abstract]

2021 Aug 11;13(8):1590. PMID: 34452455
Viruses

A Quinolinone Compound Inhibiting the Oligomerization of Nucleoprotein of Influenza A Virus Prevents the Selection of Escape Mutants. [Abstract]

2020 Mar 19;12(3):337. PMID: 32204549
J Med Virol

Discovery of ligustrazine and chalcone derivatives as novel viral nucleoprotein nuclear export inhibitors against influenza viruses. [Abstract]

2023 Jul;95(7):e28968. PMID: 37489704
J Med Virol

Establishment of a rapid ELISPOT assay for influenza virus titration and neutralizing antibody detection. [Abstract]

2021 Jun;93(6):3455-3464. PMID: 32621615
Separations

2026 Apr;13(4):105.
Peptides

Inhibition of peptide BF-30 on influenza A virus infection in vitro/vivo by causing virion membrane fusion. [Abstract]

2019 Feb:112:14-22. PMID: 30447229
Animal Model Exp Med

Antiviral effects and mechanism of Qi pi pill against influenza viruses. [Abstract]

2025 Jan 26. PMID: 39865580
SLAS Discov

High-Throughput cell-based immunofluorescence assays against influenza. [Abstract]

2024 Jan;29(1):66-76. PMID: 37925159
PLoS One

High-Efficiency Capture of Drug Resistant-Influenza Virus by Live Imaging of Sialidase Activity. [Abstract]

2016 May 27;11(5):e0156400. PMID: 27232333

Oseltamivir acid purchased from MedChemExpress. Usage Cited in: PLoS One. 2016 May 27;11(5):e0156400. [Abstract]

Live-cell fluorescence imaging of infected cells of Oseltamivir-resistant virus. MDCK cells are infected with Oseltamivir-resistant 738 and -sensitive 838. After incubation at 37°C for 12 hr, the cells are incubated with BTP3-Neu5Ac with or without Oseltamivir or Zanamivir (each 100 nM for final concentrations) in an SFM at 37°C for 10 min. Fluorescent images of the cells are observed under UV irradiation by using a fluorescence microscope. A scale bar indicates 200 μm.
PLoS One

Inhibition of influenza virus replication by targeting broad host cell pathways. [Abstract]

2014 Oct 21;9(10):e110631. PMID: 25333287
FEBS Open Bio

Construction of a convenient system for easily screening inhibitors of mutated influenza virus neuraminidases. [Abstract]

2013 Oct 29:3:484-9. PMID: 24265981
Virology

The combinatorial activities of oseltamivir and molnupiravir against influenza virus infections in vitro and in vivo. [Abstract]

2025 Oct:611:110642. PMID: 40730007
Virology

Effectiveness of favipiravir (T-705) against wild-type and oseltamivir-resistant influenza B virus in mice. [Abstract]

2020 Jun:545:1-9. PMID: 32174453
J Nat Med

Luteolin decreases the yield of influenza A virus in vitro by interfering with the coat protein I complex expression. [Abstract]

2019 Jun;73(3):487-496. PMID: 30758716
Arch Virol

Effects and mechanism of Qingke Pingchuan granules against influenza virus infection. [Abstract]

2024 May 28;169(6):130. PMID: 38807015
Arch Virol

Antiviral activity of baicalin against influenza A (H1N1/H3N2) virus in cell culture and in mice and its inhibition of neuraminidase. [Abstract]

2014 Dec;159(12):3269-78. PMID: 25078390
Biomed Chromatogr

The exploration of neuraminidase inhibitory activity on Fallopia denticulata, an ethnic herb in China. [Abstract]

2021 Apr;35(4):e5024. PMID: 33169405
Biosci Biotechnol Biochem

Orientin suppresses oxidized low-density lipoproteins induced inflammation and oxidative stress of macrophages in atherosclerosis. [Abstract]

2020 Apr;84(4):774-779. PMID: 31829093
bioRxiv

2026 Jun 10.
bioRxiv

2025 Nov 2.
Res Sq

2025 Feb 04.
bioRxiv

Oseltamivir (Tamiflu), a Commonly Prescribed Antiviral Drug, Mitigates Hearing Loss in Mice. [Abstract]

2024 May 8:2024.05.06.592815. PMID: 38765999
bioRxiv

2023 Aug 12.
bioRxiv

2020 Mar.
Chemosphere

Mass-balance-model-based evaluation of sewage treatment plant contribution to residual pharmaceuticals in environmental waters. [Abstract]

2019 Jun:225:378-387. PMID: 30884299
bioRxiv

July 26, 2018.
Biomed Pharmacother

Oroxylin A suppresses influenza A virus replication correlating with neuraminidase inhibition and induction of IFNs. [Abstract]

2018 Jan:97:385-394. PMID: 29091888

Oseltamivir acid purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2018 Jan:97:385-394. [Abstract]

The inhibitory effects of OA on M1 protein synthesis and in three different infection protocols. M1 protein expression in H1N1-infected MDCK cells analyzed by Western blot 24 h post infection.
Biomed Pharmacother

Antiviral activity of a synthesized shikonin ester against influenza A (H1N1) virus and insights into its mechanism. [Abstract]

2017 Sep:93:636-645. PMID: 28688289
Oncotarget

Virtual screening approach to identifying influenza virus neuraminidase inhibitors using molecular docking combined with machine-learning-based scoring function. [Abstract]

2017 Sep 15;8(47):83142-83154. PMID: 29137330
Evid Based Complement Alternat Med

The inhibitory effect of kakkonto, Japanese traditional (kampo) medicine, on brain penetration of oseltamivir carboxylate in mice with reduced blood-brain barrier function. [Abstract]

2015:2015:917670. PMID: 25788966

Solvant et solubilité

In Vitro:

DMSO : ≥ 230 mg/mL (808.86 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 100 mg/mL (351.68 mM; Need ultrasonic)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.5168 mL

17.5840 mL

35.1679 mL

5 mM

0.7034 mL

3.5168 mL

7.0336 mL

10 mM

0.3517 mL

1.7584 mL

3.5168 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 5.75 mg/mL (20.22 mM); Clear solution

This protocol yields a clear solution of ≥ 5.75 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (57.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 5.75 mg/mL (20.22 mM); Clear solution

This protocol yields a clear solution of ≥ 5.75 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (57.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 5.75 mg/mL (20.22 mM); Clear solution

This protocol yields a clear solution of ≥ 5.75 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (57.5 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 100 mg/mL (351.68 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact

MedChemExpress (MCE) .

Protocole

Animal Administration^[3]^[4]

Mice^[3]
Female 6-week-old BALB/c mice are anesthetized with isofluorane and intranasally inoculated with 50 μL of 10-fold serial dilutions of VN1203/04 virus in PBS. The mouse lethal dose (MLD₅₀) is calculated after a 16-day observation period. Oseltamivir is administered by oral gavage twice daily for 5 or 8 days to groups of 10 mice at dosages of 0.1, 1, and 10 mg/kg/day. Control (infected but untreated) mice received sterile PBS (placebo) on the same schedule. Four hours after the first dose of Oseltamivir, the mice are inoculated intranasally with 5 MLD₅₀ of VN1203/04 virus in 50 μL of PBS. Survival and weight change are observed for 24 days. Virus titers in the mouse organs are determined on days 3, 6, and 9 after inoculation. Three mice from each experimental and placebo group are killed, and the lungs and brains are removed. The organs are homogenized and suspended in 1 mL of PBS. The cellular debris is cleared by centrifugation at 2000 g for 5 min. The limit of virus detection is 0.75 log₁₀ EID₅₀. For calculation of the mean, samples with a virus titer <0.75 log₁₀ EID₅₀/mL are assigned a value of 0. Virus titers in each organ are calculated by use of the method of Reed and Muench and are expressed as mean log₁₀ EID₅₀/mL±SE.
Rats^[4]
Several studies are performed to characterize the pharmacokinetics of Oseltamivir and OC in the plasma, cerebrospinal fluid (CSF), and brain of Sprague-Dawley rats following single-dose bolus administration of Oseltamivir (intravenous [i.v.] and oral) and OC (i.v.). In the i.v. studies, nonfasted adult rats (two groups of 35 animals for each test substance) received a dose of 30 mg/kg body weight of either Oseltamivir or Oseltamivir carboxylate (OC) in aqueous solution with sodium chloride (0.9%; pH 4.0) via slow injection into the tail vein over 20 to 30 s. In both i.v. studies, pharmacokinetic sampling took place at 5 min and at 0.25, 0.5, 1, 2, 4, and 8 h postdose (four or five rats/time point).

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (282 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Li W, et al. Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. Antimicrob Agents Chemother. 1998 Mar;42(3):647-53. [Content Brief]

[2]. Ghosh GC, et al. Oseltamivir carboxylate, the active metabolite of oseltamivir phosphate (Tamiflu), detected in sewage discharge and river water in Japan. Environ Health Perspect. 2010 Jan;118(1):103-7. [Content Brief]

[3]. Ferraris O, et al. Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice. Antiviral Res. 2005 Oct;68(1):43-8. [Content Brief]

[4]. Gubareva LV, et al. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants.Antimicrob Agents Chemother. 2001 Dec;45(12):3403-8. [Content Brief]

[5]. Yen HL, et al. Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice. J Infect Dis. 2005 Aug 15;192(4):665-72. [Content Brief]

[6]. Hoffmann G, et al. Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. Antimicrob Agents Chemother. 2009 Nov;53(11):4753-61. [Content Brief]

[7]. Oshima S, et al. Penetration of oseltamivir and its active metabolite into the brain after lipopolysaccharide-induced inflammation in mice. J Pharm Pharmacol. 2009 Oct;61(10):1397-400. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	3.5168 mL	17.5840 mL	35.1679 mL	87.9198 mL
	5 mM	0.7034 mL	3.5168 mL	7.0336 mL	17.5840 mL
	10 mM	0.3517 mL	1.7584 mL	3.5168 mL	8.7920 mL
	15 mM	0.2345 mL	1.1723 mL	2.3445 mL	5.8613 mL
	20 mM	0.1758 mL	0.8792 mL	1.7584 mL	4.3960 mL
	25 mM	0.1407 mL	0.7034 mL	1.4067 mL	3.5168 mL
	30 mM	0.1172 mL	0.5861 mL	1.1723 mL	2.9307 mL
	40 mM	0.0879 mL	0.4396 mL	0.8792 mL	2.1980 mL
	50 mM	0.0703 mL	0.3517 mL	0.7034 mL	1.7584 mL
	60 mM	0.0586 mL	0.2931 mL	0.5861 mL	1.4653 mL
	80 mM	0.0440 mL	0.2198 mL	0.4396 mL	1.0990 mL
	100 mM	0.0352 mL	0.1758 mL	0.3517 mL	0.8792 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Oseltamivir acid

76 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Oseltamivir acid

Bioactive Compound Library Max

Bioactive Compound Library

Anti-Infection Compound Library

Metabolism/Protease Compound Library

FDA-Approved Drug Library

Antiviral Compound Library

Drug Repurposing Compound Library

Anti-COVID-19 Compound Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Drug Metabolite Library

Off-patent Drug Library

Highly Selective Inhibitors Library

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Oseltamivir acid

Activité biologique

Chemical Information

Publications (76)

Solvant et solubilité

Protocole

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Oseltamivir acid

Bioactive Compound Library Max

Bioactive Compound Library

Anti-Infection Compound Library

Metabolism/Protease Compound Library

FDA-Approved Drug Library

Antiviral Compound Library

Drug Repurposing Compound Library

Anti-COVID-19 Compound Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Drug Metabolite Library

Off-patent Drug Library

Highly Selective Inhibitors Library

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Oseltamivir acid

Activité biologique

Chemical Information

Publications (76)

Solvant et solubilité

Protocole

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Oseltamivir acid Related Classifications

HY-13318 Related Classifications